RAB-001 is under clinical development by Regenerative Arthritis & Bone Medicine and currently in Phase II for Osteoporosis. According to GlobalData, Phase II drugs for Osteoporosis have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RAB-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RAB-001 is under development for the treatment of osteoporosis, osteonecrosis, fracture healing and rheumatoid arthritis. The drug candidate is a peptide drug conjugate (PDC) which acts by targeting alpha4beta1 integrin on mesenchymal stem cells (MSCs). It is administered through intravenous and parenteral route.
For a complete picture of RAB-001’s drug-specific PTSR and LoA scores, buy the report here.